A practical reference on peptide research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
=== Bottom-up methods === Bottom-up methods involve the assembly of atoms or molecules into nanostructured arrays. In these methods the raw material sources can be in the form of gases, liquids, or solids. The latter require some sort of disassembly prior to their incorporation onto a nanostructure. Bottom up methods generally fall into two categories: chaotic and controlled. Chaotic processes involve elevating the constituent atoms or molecules to a chaotic state and then suddenly changing the conditions so as to make that state unstable. Through the clever manipulation of any number of parameters, products form largely as a result of the insuring kinetics. The collapse from the chaotic state can be difficult or impossible to control and so ensemble statistics often govern the resulting size distribution and average size. Accordingly, nanoparticle formation is controlled through manipulation of the end state of the products. Examples of chaotic processes are laser ablation, exploding wire, arc, flame pyrolysis, combustion, and precipitation synthesis techniques. Controlled processes involve the controlled delivery of the constituent atoms or molecules to the site(s) of nanoparticle formation such that the nanoparticle can grow to a prescribed sizes in a controlled manner. Generally the state of the constituent atoms or molecules are never far from that needed for nanoparticle formation. Accordingly, nanoparticle formation is controlled through the control of the state of the reactants.
That Awkward Moment (released as Are We Officially Dating? in Australia, Indonesia, and New Zealand) is a 2014 American bromantic comedy drama film written and directed by Tom Gormican in his directorial debut. The film stars Zac Efron, Miles Teller, Michael B. Jordan, Imogen Poots, Mackenzie Davis, and Jessica Lucas. The film had its Los Angeles premiere on January 27, 2014, and it was widely released on January 31 in the United States.
Historians have noted that Chinese scholars wrote these studies instead of "books of prescriptions or advice manuals." In their historical and environmental understanding, no two illnesses were alike, so the healing strategies of the practitioner were unique every time to the specific diagnosis of the patient. Medical case studies existed throughout Chinese history, but "individually authored and published case history" was a prominent creation of the Ming dynasty. An example of such case studies would be the literati physician, Cheng Congzhou, collection of 93 cases published in 1644.
The empire's inhabitants, today generally known as Byzantines, regarded themselves as Romans (in Greek, Ῥωμαῖοι or Romaioi). Similarly, their Islamic contemporaries called their empire the "land of the Romans" (Bilād al-Rūm). After 800 AD, Western Europe called them "Greeks" (Graeci), as the Papacy and medieval German emperors regarded themselves as the true inheritors of Roman identity. The adjective "Byzantine", derived from Byzantion (Byzantium in Latin), the name of the Greek settlement Constantinople was established on, was only used to describe the inhabitants of the city; it did not refer to the empire, called Rhomanía (Ῥωμανία or "Romanland") by its citizens. Following the empire's fall, early modern scholars referred to it by many names, including the "Eastern Empire", the "Low Empire", the "Late Empire", the "Empire of the Greeks", "Empire of Constantinople", and "Roman Empire". The increasing use of "Byzantine" and "Byzantine Empire" may have started with Theodore Metochites or Laonikos Chalkokondyles whose work was widely propagated by Hieronymus Wolf. "Byzantine" was used adjectivally alongside terms such as "Empire of the Greeks" until the 19th century. It is now the primary term, used to refer to all aspects of the empire; some modern historians believe it should not be used because it was originally a prejudicial and inaccurate term.
Sources: en.wikipedia.org
2A peptides are a class of 18–22 aa-long peptides, which can induce ribosomal skipping during translation of a protein in a biological cell. These peptides share a core sequence motif of DxExNPGP, and are found in a wide range of viral families. 2A peptides can be introduced artificially to help generate polyproteins from a single ORF, by causing the ribosome to fail at making a peptide bond, and then resume translation. The members of 2A peptides are named after the virus in which they have been first described. For example, F2A, the first described 2A peptide, is derived from foot-and-mouth disease virus. The name "2A" itself comes from the gene numbering scheme of this virus. These peptides are also known as "self-cleaving" peptides, which is a known misnomer, because the missing peptide bond is never synthesized by the ribosome, and is thus not cleaved.
== Age-related prevalence of the CKM syndrome == A study of 231,590,853 individuals living in the USA found older aged patients trended to have higher stages of the CKM syndrome. In the 20-44 years old age group 17.3% were stage 0, 37.6% were stage 1, 43.2% % were stage 2, 0.2% were stage 3, and 1.7% were stage 4. In the 45 to 64 years old group, 5.4% were stage 0, 21.0% were stage 1, 63.8% were stage 2, 1.2 % were stage 3, and 8.6% were stage 4. In the 65 years and older age group, 1.8% were stage 0, 8.4% were stag 1, 39.0% were stage 2, 24.6% were stage 3, and 26.2% were stage 4. The 20 to 44, 45 to 64, and 65 or greater years old groups consisted respectively of 104,113,793, 82,640,261, and 44,836,799 individuals.
=== Excretion === After administration of ibutilide, it is quickly excreted by renal pathway with a half-life of approximately 6 hours. Approximately 82% of a 0.01 mg/kg dose is excreted in the urine during the trial. Among those, around 7% is excreted as unchanged drug. The remainder of the drug is excreted in feces (about 19%).
Sources: en.wikipedia.org
They built on the character of the Aperture Science facility, providing a deeper story for GLaDOS and Aperture's CEO Cave Johnson, as well as developing several concepts for "personality cores" that ultimately led to the creation of Wheatley. Portal 2 received similar acclaim to its predecessor at launch, garnering a Metacritic score of 95 out of 100. Valve has continued to support the game through the release of two separate downloadable content packages, one introducing a new co-operative campaign, and a second that incorporated an easy-to-learn level editor that allowed players to make their own test chambers and share these through the Steam Workshop to others. An alternate version of Portal 2 designed for educational use was developed for Valve's Steam for Schools program, and was made available for free. While experimenting with VR systems in 2017, Valve attempted to implement Portal-like gameplay, but early playtesters found the game's titular mechanic disorienting in VR. Valve instead returned to the Half-Life series and released Half-Life: Alyx in 2020. In April 2022, Erik Wolpaw urged Valve to make Portal 3, saying, "I am... not getting any younger. We are reaching the point where – it's crazy to think – [we're] literally going to be too old to work on Portal 3. So we should just do it." In September, Ellen McLain also called for Portal 3, stating that she was willing to star in it, and asked fans to "write in. Email Valve. You've got my blessing".
=== Legal status === In June 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Onswik, intended for the treatment of type 2 diabetes. The applicant for this medicinal product is Eli Lilly Nederland. Insulin efsitora alfa was authorized for medical use in the European Union in August 2026. Insulin efsitora alfa was approved for medical use in the United States in September 2026.
In ruling on the 1986 Huanchaca case involving the slaying of a leading Bolivian scientist, his pilot, and a guide, the Third Criminal Court of Santa Cruz returned a guilty verdict in April 1988 against ten Brazilians and a Colombian, in addition to a Bolivian thought to be dead. The court, however, dismissed charges against five other Bolivian suspects, including several well-known drug traffickers. The freeing of two of the suspects by the Santa Cruz judges prompted the Supreme Court of Justice to demand the resignations of the entire Santa Cruz judiciary because of its leniency toward drug traffickers. Four Santa Cruz judges were dismissed because of irregularities in the Huanchaca case, which in early 1989 remained at an impasse, under advisement in the Supreme Court of Justice. Drug kingpin Roberto Suárez Gómez was arrested in 1988. Under the 1988 Antinarcotics Law, the Judicial Police must report antinarcotics operations to the closest Special Antinarcotics Force district within forty-eight hours. The law also called for the creation of three-judge Special NarcoticsControl Courts or tribunals (Juzgados Especiales de Narcotráfico) with broad responsibilities. In early 1989, the Supreme Court of Justice began appointing judges and lawyers to serve on the new tribunals, two of which began functioning as tribunals of first instance in narcotics-related cases, with jurisdiction for the judicial districts of La Paz, Cochabamba, Santa Cruz, and Beni.
In the early stages after the procedure, the use of interdental brushes is strongly advised against due to the potential damage to interdental tissues in the operated area, toothpicks are recommended as an alternative. The patient is asked to visit every two weeks for monitoring of their plaque levels. The time between visits will gradually increase if the patients’ plaque control is up to standard.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.